AAD 2019: Sonidegib Effective in Aggressive and Nonaggressive Basal Cell Carcinoma
Adverse events were largely grade 1 to 2 and manageable
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Adverse events were largely grade 1 to 2 and manageable
Only registered members have full access to PracticeUpdate content.